AMX-883: A Novel BRD9 Molecular Glue Degrader for Acute Myeloid Leukemia Research

AMX-883 is an orally bioavailable BRD9 molecular glue degrader attracting attention in acute myeloid leukemia research. Unlike traditional inhibitors, AMX-883 is designed to remove BRD9 protein from cells, potentially disrupting chromatin remodeling and leukemia-associated transcriptional programs. By promoting BRD9 degradation through a DCAF16-mediated pathway, AMX-883 offers a useful approach for studying targeted protein degradation beyond common CRBN- or VHL-based systems. Preclinical findings suggest that BRD9 degradation may affect AML cell survival, differentiation, and leukemic burden. Although AMX-883 remains a development-stage compound, it represents a promising direction in molecular glue drug discovery and epigenetic cancer research.

Introduction: Why AMX-883 Is Attracting Attention

AMX-883 is emerging as a noteworthy compound in the field of targeted protein degradation, particularly for acute myeloid leukemia (AML) research. Developed as an orally bioavailable BRD9 molecular glue degrader, AMX-883 is designed to eliminate BRD9 protein rather than simply inhibit its activity. This distinction is important because protein degradation strategies may offer a more complete and sustained way to modulate disease-relevant targets involved in cancer cell survival and differentiation.

BRD9 is a bromodomain-containing protein associated with chromatin remodeling and epigenetic regulation. In AML, abnormal gene expression programs can support leukemic cell growth and block normal blood cell differentiation. By selectively degrading BRD9, AMX-883 provides researchers with a valuable tool to investigate how disruption of BRD9-dependent pathways may affect leukemia biology.

The compound also reflects the broader rise of molecular glue degraders in oncology drug discovery. Unlike traditional small-molecule inhibitors, molecular glues work by bringing a target protein into proximity with an E3 ligase, leading to its degradation by the cellular proteasome system. As interest in targeted protein degradation continues to grow, AMX-883 has attracted attention as a selective BRD9 degrader with potential relevance for next-generation AML therapeutic strategies.

Background: BRD9 and Its Role in Cancer Biology

BRD9 is a bromodomain-containing protein involved in chromatin remodeling, a process that helps regulate how genetic information is accessed and expressed inside cells. It is a component of the non-canonical BAF complex, also known as the ncBAF or GBAF complex, which participates in controlling gene transcription. Because cancer cells often depend on abnormal transcriptional programs to sustain growth, survival, and resistance to differentiation, BRD9 has become an important target in epigenetic cancer research.

In acute myeloid leukemia, disrupted gene regulation plays a central role in maintaining leukemic cells in an immature and proliferative state. BRD9 may contribute to these disease-associated transcriptional networks by supporting chromatin states that favor leukemia cell survival. As a result, researchers are increasingly interested in strategies that interfere with BRD9 function or remove the BRD9 protein altogether.

The development of BRD9 degraders such as AMX-883 reflects this growing interest. Instead of only blocking the bromodomain activity of BRD9, degradation-based approaches aim to eliminate the protein from the cell, potentially disrupting both enzymatic and structural functions. This makes BRD9 degradation a valuable research strategy for studying AML biology, epigenetic regulation, and new therapeutic directions in hematologic malignancies.

Mechanism of Action: How AMX-883 Degrades BRD9

AMX-883 functions as a molecular glue degrader designed to selectively remove BRD9 from cancer cells. Unlike a conventional inhibitor, which mainly blocks the activity of a target protein, a degrader promotes the destruction of the protein itself. This distinction is important for BRD9 because the protein may contribute to cancer biology not only through its bromodomain activity, but also through its role as part of chromatin remodeling complexes.

As a molecular glue, AMX-883 works by encouraging a new interaction between BRD9 and an E3 ubiquitin ligase complex. This interaction marks BRD9 for ubiquitination, a cellular tagging process that directs proteins to the proteasome for degradation. Reported data indicate that AMX-883 uses the DCAF16 pathway to drive BRD9 degradation, distinguishing it from many degraders that rely on CRBN or VHL-based mechanisms.

By reducing BRD9 protein levels, AMX-883 may more broadly disrupt BRD9-dependent transcriptional programs in acute myeloid leukemia cells. This degradation-based mechanism allows researchers to study how complete target removal affects AML cell survival, differentiation, and epigenetic regulation, making AMX-883 a valuable compound in targeted protein degradation research.

Preclinical Evidence in Acute Myeloid Leukemia

Preclinical studies have positioned AMX-883 as a promising BRD9 degrader for acute myeloid leukemia research. AML is an aggressive hematologic malignancy characterized by uncontrolled growth of immature myeloid cells and impaired normal blood cell differentiation. Because epigenetic dysregulation is a key feature of AML biology, compounds that interfere with chromatin-associated proteins such as BRD9 are of strong interest in drug discovery.

AMX-883 has been reported to induce selective BRD9 degradation and trigger anti-leukemic effects in AML models. In preclinical research, BRD9 degradation may help disrupt transcriptional programs that maintain leukemic cell survival and block differentiation. This makes AMX-883 useful for studying whether removing BRD9 can push AML cells toward a more differentiated and less proliferative state.

Research findings also suggest that AMX-883 has activity in AML cell models and patient-derived systems, supporting its potential relevance beyond standard cell-line screening. Animal model data further indicate that BRD9 degradation may reduce leukemic burden in vivo. However, AMX-883 remains a development-stage compound, and its clinical safety, pharmacokinetics, optimal dosing, and therapeutic efficacy still require further investigation in human studies.

AMX-883 in the Targeted Protein Degradation Landscape

AMX-883 represents an important example of how targeted protein degradation is expanding beyond traditional PROTAC design. In recent years, targeted protein degradation has become a major strategy in drug discovery because it offers a way to remove disease-relevant proteins rather than simply inhibit them. This approach is especially valuable for proteins involved in complex regulatory networks, including epigenetic and transcription-associated targets such as BRD9.

Within this landscape, AMX-883 is notable because it is designed as a molecular glue degrader. Molecular glues are typically smaller and structurally simpler than many PROTAC molecules, and they work by promoting interactions between a target protein and an E3 ligase. For AMX-883, the target is BRD9, a chromatin-associated protein implicated in AML biology. By inducing BRD9 degradation, AMX-883 provides a useful research model for exploring how selective protein removal may affect leukemia cell growth, survival, and differentiation.

The compound also highlights the growing diversity of E3 ligase recruitment strategies. While many degraders rely on CRBN or VHL, AMX-883 has been associated with DCAF16-mediated degradation. This makes it relevant not only for AML research, but also for the broader study of molecular glue drug discovery and next-generation targeted protein degradation technologies.

Future Outlook: Research Potential and Clinical Development

AMX-883 represents a promising direction in targeted protein degradation research, particularly for acute myeloid leukemia. As an orally bioavailable BRD9 molecular glue degrader, it may provide researchers with a new way to investigate how selective BRD9 removal affects leukemia cell survival, differentiation, and disease progression. Its reported use of DCAF16-mediated degradation also makes it valuable for studying alternative E3 ligase pathways beyond the more commonly used CRBN and VHL systems.